The disease-free-survival(DFS)at 5 years post-ABMT were 50.5%for all patients and 61.2% for acute myeloid leukemia(AML)at a median follow-up of 18 months.

• 中位随访18个月，5年无病生存率为50.；5%25，其中急性髓系白血病（AML）为61